Trial Profile
A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 06 Apr 2020 Status changed from active, no longer recruiting to completed.
- 19 Oct 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 19 Oct 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.